Genuinely perplexed? Its like someone was short selling it down (they are not). Even if you (stupidly) put J&J take over probability at zero, you have the BioHorizon deal. You have a run of very good personnel additions to advisory boards, the board and the executive team all utterly geared towards Remplir, CleGro Tendon and ATI approval. US regulatory and reimbursement specialists. Remplir will very likely be partnered very quickly. Striate was and its the least appealing of CelGro's application!
ATI's potential is huge and is a very real pathway. Huge tidal change of autologous cellular therapy approvals by the FDA in the US in the last two years. Clearly very few have looked at Carvykti which J&J are predicting could reach $5 billion in global sales! ATI could be far more easily and extensively applied to the general population in terms of medical needs.
ACI, basically turning Vericel from a half billion dollar burns focused company into a $1.6 billion osteoarthritis focused company ion a $55 million original outlay.
Comical mkts.
OCC Price at posting:
37.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)